Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL746643 | 0.83 | ATM (0.59) | ATMALDH1A1XDHCYP2A6CYP11B1 | |
| SCHEMBL1185505 | 0.82 | GPR119 (0.43) | ATMXDHCYP11B1CYP11B2RAF1 | |
| SCHEMBL509479 | 0.82 | CYP2C9 (0.62) | ATMALDH1A1CYP11B1CYP11B2KDM4E | |
| SCHEMBL23012593 | 0.81 | ATM (0.57) | ATMALDH1A1XDHCYP2A6CYP11B1 | |
| SCHEMBL56951 | 0.81 | ATM (0.77) | ATMALDH1A1XDHCYP2A6CYP11B1 | |
| SCHEMBL9296654 | 0.80 | CYP11B2 (0.50) | ALDH1A1XDHCYP11B1CYP11B2RAF1 | |
| SCHEMBL2228514 | 0.80 | CA1 (0.52) | ATMALDH1A1XDHCYP11B1CYP11B2 | |
| SCHEMBL4747234 | 0.80 | CA12 (0.52) | ALDH1A1XDHCYP11B1CYP11B2KDM4E | |
| SCHEMBL3818674 | 0.79 | XDH (0.49) | ALDH1A1XDHKDM4EGRM5EGLN2 | |
| Hydrochloric Acid SCHEMBL2298745 | 0.79 | ATM (0.74) | ATMALDH1A1XDHCYP2A6CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-116120226-A | Synthesis process of 5-hydroxymethyl nicotinonitrile | 湖南阿斯迪康药业有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115052873-A | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | 勃林格殷格翰国际有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022155419-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2022-07-21 | — | — | WO | disclosed |
| CN-111825654-A | Phenylmethylene piperidine derivatives, preparation method, intermediates and uses thereof | 北京酷瓴生物技术有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2020211836-A1 | BENZENE PIPERIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF | 北京酷瓴生物技术有限公司 | 2020-10-22 | — | — | WO | disclosed |
| EP-3704113-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| CN-111295382-A | Bridged bicyclic compounds as modulators of farnesoid X receptors | 百时美施贵宝公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| EP-1699761-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005066126-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| CN-1043760-C | \"Pyridinecarboximidamide compounds and the use thereof\ | KIRN BEER KABUSHIKI KAISHA (JP) | 1999-06-23 | — | — | CN | disclosed |
| EP-0634400-B1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BREWERY (JP) | 1997-04-02 | — | — | EP | disclosed |
| US-5508293-A | TREATING HYPERTENSION, ANGINA PECTORIS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1996-04-16 | — | — | US | disclosed |
| EP-0634400-A1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BEER KABUSHIKI KAISHA (JP) | 1995-01-18 | — | — | EP | disclosed |
| CN-1077949-A | Pyridine carboxy imido acid amide compound and application thereof | KIRIN BREWERY (JP) | 1993-11-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | ATM 2665/4885ALDH1A1 3227/4885XDH 3389/4885 |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, NR1H2 | ATM 2252/4885ALDH1A1 2602/4885XDH 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.